Nuzenio

Why Sarepta Therapeutics

Why Sarepta Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 20 latest news signals 9 publisher sources 100/100 entity strength

Latest news

Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO - simplywall.stsimplywall.st · Mon, 10 Aug 2026 05:32:52 GMTSRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - StocktwitsStocktwits · Sat, 08 Aug 2026 23:05:33 GMTSarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - StocktwitsStocktwits · Sat, 08 Aug 2026 11:59:18 GMTSarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer - simplywall.stsimplywall.st · Sat, 08 Aug 2026 10:47:26 GMTSarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - StocktwitsStocktwits · Fri, 07 Aug 2026 17:26:02 GMTState Street (NYSE: STT) discloses 8.4% Sarepta Therapeutics ownership via Schedule 13G - stocktitan.netstocktitan.net · Fri, 07 Aug 2026 14:55:22 GMTSarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - StocktwitsStocktwits · Fri, 07 Aug 2026 12:06:44 GMTSarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop - simplywall.stsimplywall.st · Fri, 07 Aug 2026 00:04:01 GMT

Timeline

Mon, 10 Aug 2026 05:32:52 GMTWhy Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO - simplywall.st
Sat, 08 Aug 2026 23:05:33 GMTSRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
Sat, 08 Aug 2026 11:59:18 GMTSarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Sat, 08 Aug 2026 10:47:26 GMTSarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer - simplywall.st
Fri, 07 Aug 2026 17:26:02 GMTSarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
Fri, 07 Aug 2026 14:55:22 GMTState Street (NYSE: STT) discloses 8.4% Sarepta Therapeutics ownership via Schedule 13G - stocktitan.net

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Why Sarepta Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

9 distinct publisher/source names are currently connected to this entity page.